The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
 
Laura Quan Man Chow
Consulting or Advisory Role - Alkermes; Cullinan Management; Dynavax Technologies; Merck; Novartis; Pfizer; Synthorx
Research Funding - ALX Oncology (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Incyte (Inst); Lilly/ImClone (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; Jounce Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Nehal J. Lakhani
Consulting or Advisory Role - Innovent Biologics
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Formation Biologics (Inst); Forty Seven (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Keun Wook Lee
Honoraria - Bristol-Myers Squibb; Genexine; Lilly
Consulting or Advisory Role - Bayer
Research Funding - ALX Oncology (Inst); Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Jeeyun Lee
Consulting or Advisory Role - Oncologie; Seagen
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; GlaxoSmithKline; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Compass Therapeutics; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Rafael Santana-Davila
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Genentech/Roche; Lilly; PharmaMar
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); Genentech (Inst); Lilly (Inst)
 
Philip Fanning
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
Travel, Accommodations, Expenses - ALX Oncology
 
Pierre Squifflet
Employment - IDDI
Consulting or Advisory Role - ALX Oncology (Inst)
 
Feng Jin
Employment - Theravance
Consulting or Advisory Role - Alx oncology; Alx oncology
 
Hong Wan
Employment - ALX Oncology
Leadership - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology; Pfizer
Patents, Royalties, Other Intellectual Property - patents on targeting CD47-SIRPa
Travel, Accommodations, Expenses - ALX Oncology
 
Tracy Kuo
No Relationships to Disclose
 
Jaume Pons
Employment - ALX Oncology
Leadership - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
Consulting or Advisory Role - Teva
Patents, Royalties, Other Intellectual Property - ALX Oncology
Travel, Accommodations, Expenses - ALX Oncology
 
Sophia Randolph
Employment - ALX Oncology
Stock and Other Ownership Interests - Carrick Therapeutics; Pfizer
Consulting or Advisory Role - venBio
 
Wells A. Messersmith
Consulting or Advisory Role - Five Prime Therapeutics (Inst); Gilead Sciences (Inst); Purdue Pharma (Inst); Tanabe Research (Inst)
Research Funding - Aduro Biotech (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); Beigene (Inst); D3 (Inst); Immunomedics (Inst); OncoMed (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)